Valeant Pharmaceuticals, Express Scripts sales and marketing update

Express Scripts said it excluded Valeant’s Glumetza metformin to treat Type II diabetes from its 2016 formulary. Lupin Ltd. (NSE:LUPIN; BSE:500257, Mumbai, India) launched a generic version of the extended-release formulation of metformin last week. Express Scripts said it excluded Glumetza due to agreements Valeant made with retail pharmacies that would “potentially encourage the pharmacies to bypass the more affordable generic metformin and instead dispense branded Glumetza at a higher cost to American payers.” ...